Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
暂无分享,去创建一个
[1] J. E. Muñoz-Medina,et al. Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population , 2023, Microbiology spectrum.
[2] Dong Ho Kim,et al. Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19 , 2022, Vaccines.
[3] Howard D Larkin. New Data on Heterologous COVID-19 Vaccine Combinations. , 2022, Journal of the American Medical Association (JAMA).
[4] J. Sánchez-Payá,et al. Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain , 2022, Vaccine.
[5] V. Haselmann,et al. Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)—Pitfalls of Routine Application , 2022, Viruses.
[6] N. Toyota,et al. Long-term observation of antibody titers against SARS-CoV-2 following vaccination , 2022, Public Health in Practice.
[7] S. Clouston,et al. Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response , 2022, Clinical Imaging.
[8] S. Fujitani,et al. Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19 , 2022, Scientific Reports.
[9] E. Ali,et al. COVID-19 Vaccine-Induced Cerebral Sinus Thrombosis: Coincidence vs. Cause? , 2022, Cureus.
[10] E. Undurraga,et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study , 2022, The Lancet Global Health.
[11] Y. Poovorawan,et al. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data , 2022, Vaccine.
[12] A. Apisarnthanarak,et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study , 2022, Emerging microbes & infections.
[13] Y. Poovorawan,et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study , 2022, Human vaccines & immunotherapeutics.
[14] D. Montefiori,et al. Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.
[15] B. Walker,et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals , 2022, medRxiv.
[16] A. Hoerauf,et al. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines , 2021, Frontiers in Immunology.
[17] C. Broder,et al. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers , 2021, Open forum infectious diseases.
[18] Aaron M. Rosenfeld,et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.
[19] D. Montefiori,et al. Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report , 2021, medRxiv.
[20] Mathias W Pletz,et al. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection , 2021, Viruses.
[21] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.
[22] C. Castilletti,et al. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine , 2021, Clinical chemistry and laboratory medicine.
[23] A. Iwasaki,et al. Prevention of host-to-host transmission by SARS-CoV-2 vaccines , 2021, The Lancet Infectious Diseases.
[24] J. Marschall,et al. Serological testing for SARS‐CoV‐2 antibodies in clinical practice: A comparative diagnostic accuracy study , 2021, Allergy.
[25] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[26] D. Prieto-Alhambra,et al. Heterologous vaccine regimens against COVID-19 , 2021, The Lancet.
[27] D. O’Connor,et al. Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2 , 2021, ImmunoHorizons.
[28] V. Haselmann,et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection , 2021, International Journal of Infectious Diseases.
[29] M. Sutton,et al. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England , 2021, BMC Medicine.
[30] A. Griesmacher,et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers , 2021, Clinical chemistry and laboratory medicine.
[31] P. McKay,et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.
[32] M. Nussenzweig,et al. Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.
[33] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[34] Jianguo Wu,et al. COVID-19: Coronavirus Vaccine Development Updates , 2020, Frontiers in Immunology.
[35] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[36] Rebecca J. Loomis,et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.
[37] F. Baldanti,et al. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively , 2020, Journal of Clinical Microbiology.
[38] S. Yerly,et al. Validation of a commercially available SARS-CoV-2 serological immunoassay , 2020, Clinical Microbiology and Infection.
[39] P. T. Ten Eyck,et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.
[40] Alan D. Roberts,et al. Antibody-Independent Antiviral Function of Memory CD4+ T Cells In Vivo Requires Regulatory Signals from CD8+ Effector T Cells1 , 2001, The Journal of Immunology.
[41] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .